Sleep Aids - G20

  • G20
  • Revenue in the Sleep Aids market amounts to US$4.97bn in 2024. The market is expected to grow annually by 4.69% (CAGR 2024-2029).
  • In global comparison, most revenue is generated in the United States (US$2,103m in 2024).
  • In relation to total population figures, per person revenues of US$1.00 are generated in 2024.

Key regions: Philippines, Indonesia, United Kingdom, Canada, Thailand

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Sleep Aids market in G20 countries is experiencing significant growth due to changing customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors.

Customer preferences:
Customers in G20 countries are increasingly prioritizing their sleep health and seeking solutions to improve their quality of sleep. This shift in customer preferences is driven by various factors such as increased awareness about the importance of sleep for overall well-being, rising stress levels, and the growing prevalence of sleep disorders. As a result, there is a growing demand for sleep aids that can help individuals fall asleep faster, stay asleep longer, and wake up feeling refreshed.

Trends in the market:
One of the key trends in the Sleep Aids market in G20 countries is the rising popularity of natural and non-habit-forming sleep aids. Customers are becoming more conscious about the ingredients used in sleep aids and are opting for products that are derived from natural sources and have minimal side effects. This trend is driven by the increasing focus on health and wellness, as well as the desire to avoid dependency on medication. Another trend in the market is the growing adoption of technological advancements in sleep aids. Customers are increasingly using wearable devices, smartphone apps, and smart home devices to track and improve their sleep quality. These technologies provide personalized insights and recommendations to help individuals optimize their sleep patterns, leading to a higher demand for sleep aids that can integrate with these devices and platforms.

Local special circumstances:
The Sleep Aids market in G20 countries is also influenced by local special circumstances. For example, in countries with aging populations, there is a higher prevalence of sleep disorders such as insomnia and sleep apnea. This creates a larger customer base for sleep aids and drives market growth. Additionally, cultural factors and lifestyle choices can also impact the demand for sleep aids. For instance, countries with a fast-paced and highly competitive work culture may see higher demand for sleep aids to help individuals manage stress and improve sleep quality.

Underlying macroeconomic factors:
The Sleep Aids market in G20 countries is also influenced by underlying macroeconomic factors. Economic growth, rising disposable incomes, and increasing healthcare expenditure contribute to the growth of the market. As individuals have more financial resources, they are more likely to invest in sleep aids to improve their sleep quality. Furthermore, the prevalence of sleep disorders is also influenced by factors such as urbanization, lifestyle changes, and access to healthcare services, which in turn impact the demand for sleep aids. In conclusion, the Sleep Aids market in G20 countries is witnessing significant growth due to changing customer preferences, the adoption of natural and non-habit-forming sleep aids, the integration of technology, local special circumstances, and underlying macroeconomic factors. As customers prioritize their sleep health and seek solutions to improve their sleep quality, the market is expected to continue growing in the coming years.

Methodology

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)